Light-Activated ointment shows promise for rare skin cancer
NCT ID NCT05872854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a synthetic ointment (HyBryte) activated by visible light to treat mycosis fungoides, a type of skin lymphoma. Ten adults with early-stage disease received treatment for up to 54 weeks. The goal was to see if the ointment could reduce redness, scaling, and plaque thickness on the skin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19034, United States